Skip to main content
Year archive

Mabpharm Limited — 2023 filings

All 29 regulatory filings released by Mabpharm Limited (2181) in 2023, sourced directly from the official regulator.

29 Filings
2023 Period
2023 filings (29)
Filing Released Lang
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
Regulatory Filings
2023-12-04 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Regulatory Filings
2023-11-28 English
(1) RESIGNATION OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR (2) APPOINTMENT OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR
Regulatory Filings
2023-11-28 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Regulatory Filings
2023-11-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
Regulatory Filings
2023-10-04 English
2023 Interim Report
Regulatory Filings
2023-09-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
Regulatory Filings
2023-09-04 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
Regulatory Filings
2023-08-25 English
VOLUNTARY ANNOUNCEMENT BUSINESS COOPERATION AGREEMENT WITH JIANGSU SIMCERE ZAIMING IN RELATION TO CMAB009 IN CHINA
Regulatory Filings
2023-08-20 English
DATE OF BOARD MEETING
Regulatory Filings
2023-08-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
Regulatory Filings
2023-08-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023
Regulatory Filings
2023-07-04 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY, 16 JUNE 2023
Regulatory Filings
2023-06-16 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023
Regulatory Filings
2023-06-06 English
INSIDE INFORMATION ANNOUNCEMENT APPROVAL FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ON THE NEW DRUG APPLICATION (NDA) OF OUR CORE PRODUCT, CMAB007 (OMALIZUMAB ALFA FOR INJECTION)
Regulatory Filings
2023-05-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
Regulatory Filings
2023-05-05 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 16, 2023
Regulatory Filings
2023-04-20 English
NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2023-04-20 English
PROPOSED RE-ELECTION OF DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2023-04-20 English
2022 Annual Report
Regulatory Filings
2023-04-20 English
VOLUNTARY ANNOUNCEMENT EXCLUSIVE PROMOTION AGREEMENT WITH JEMINCARE IN RELATION TO CMAB007 IN CHINA
Regulatory Filings
2023-04-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
Regulatory Filings
2023-04-04 English
Terms of reference of the Remuneration Committee
Regulatory Filings
2023-03-24 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022
Regulatory Filings
2023-03-24 English
DATE OF BOARD MEETING
Regulatory Filings
2023-03-15 English
INSIDE INFORMATION ANNOUNCEMENT ACCEPTANCE OF THE NEW DRUG APPLICATION (NDA) OF OUR CORE PRODUCT CMAB009 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings
2023-03-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023
Regulatory Filings
2023-03-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
Regulatory Filings
2023-02-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
Regulatory Filings
2023-01-04 English